USFDA approves Sun Pharma's generic Xanax ANDA

Download PDF Copy

Jun 18 2010

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Xanax®, alprazolam tablets.

These generic alprazolam tablets, equivalent to Pfizer's Xanax® tablets, include four strengths: 0.25 mg, 0.5 mg, 1 mg and 2 mg. Annual sale in US for these strengths of branded and generic alprazolam tablets is estimated at $145 million.

Alprazolam tablets are indicated for the management of anxiety disorder or the short-term relief of symptoms of anxiety. It is also indicated for the treatment of panic disorder, with or without agoraphobia.

Source:

Sun Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Tags: Agoraphobia, Anxiety, Anxiety Disorder, Cardiology, Gastroenterology, Neurology, New Drug Application, Panic Disorder, Pharmaceuticals, Psychiatry, Xanax

Comments (1)

Download PDF Copy

Suggested Reading

Does living near green space help soothe early childhood anxiety and depression?

Study confirms the mental health benefits of weight training for older individuals

Treatment for anxiety and depression associated with improved heart disease outcomes

Cannabis compound d-limonene reduces anxiety-inducing effects of THC

Is psilocybin safe for treating depression and anxiety?

Good vibrations could provide a helping hand to people living with social anxiety

Metabolic markers tied to increased risk of depression and anxiety, study finds

Study finds digital CBT for children with anxiety delivers on par with traditional methods, lowers costs

Comments

proven clinicly contains 2m,.g, alorazolam ?

paul carlson says:

June 1, 2012 at 9:55 AM

Being a new product marketed by 'SUN PHARMA" and approved by the FDA; Plaese provide data on location of Pharmaceutical plant;any violations of strict 'sterile environment.
I have tested your approved 2m.g. generic xanax. I was prescribed sun pharma,please inform me that sun pharma is manufactured in the U.S.A.If not the word will spread, sun pharma is weak and patients suffer to save afew bucks. The public knows about counterfiet medicine from China, India And north Korea etc. management make adjustments. Do the right thing.

'

0 0

Reply